Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Chloroquine AND (Coronavirus 2019 OR COVID-19 OR SARS-CoV-2))
44 results
  • Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. [Review]
    Clin Pharmacol Ther. 2020 Apr 04 [Online ahead of print]Du YX, Chen XP
  • An outbreak of 2019-nCoV infection in China has spread across the world. No specific antiviral drugs have been approved for the treatment of COVID-2019. In addition to the recommended antiviral drugs such as interferon-ɑ, lopinavir/ritonavir, ribavirin, and chloroquine phosphate, some clinical trials focusing on virus RNA dependent RNA polymerase (RdRp) inhibitors have been registered and initiat…
  • Potential therapeutic agents against COVID-19: What we know so far. [Journal Article]
    J Chin Med Assoc. 2020 Apr 01 [Online ahead of print]Lu CC, Chen MY, Chang YL
  • The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic …
  • Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic. [Journal Article]
    J Rheumatol. 2020 Apr 02 [Online ahead of print]Scuccimarri R, Sutton E, Fitzcharles MA
  • Two antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ), have been trusted treatments for a range of rheumatic diseases over the past seventy years [1]. These agents have attracted intense media attention in the past few weeks with suggestions that this category of drugs may have potential in the management of coronavirus (SARS-CoV2) associated disease called COVID-19 [2, 3].
  • The epidemiology, diagnosis and treatment of COVID-19. [Journal Article]
    Int J Antimicrob Agents. 2020 Mar 28 [Online ahead of print]Zhai P, Ding Y, … Li Y
  • In December 2019, the outbreak of the 2019 novel coronavirus disease (COVID-19) in China spread worldwide, becoming an emergency of major international concern. SARS-CoV-2 infection causes clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus. Human-to-human transmission has been described with incubation times between 2-14 days, facilitating its spread v…
  • Chloroquine in COVID-19: the evidence. [Journal Article]
    Monaldi Arch Chest Dis. 2020 Mar 31; 90(1)Gupta N, Agrawal S, Ish P
  • To the Editor The Coronavirus disease 2019 (COVID-19) has been declared as a pandemic by World Health Organisation (WHO). The global mortality has increased, especially in countries like Italy and Iran. With the increasing morbidity and mortality, search for a cure has been the global demand.
  • Emerging prophylaxis strategies against COVID-19. [Review]
    Monaldi Arch Chest Dis. 2020 Mar 30; 90(1)Agrawal S, Goel AD, Gupta N
  • The Novel corona virus 2019 which started as an outbreak in China in December 2019 has rapidly spread all over the world, such that on 11th March 2020 WHO declared this disease as pandemic. The emergency that the world faces today demands that we develop urgent and effective measures to protect people at high risk of transmission. WHO has accelerated research in diagnostics, vaccines and therapeu…
  • Controversial treatments: an updated understanding of the Coronavirus Disease 2019. [Review]
    J Med Virol. 2020 Mar 26 [Online ahead of print]Zhang C, Huang S, … Dai Y
  • An outbreak of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection has posed significant threats to international health and the economy. In the absence of specific treatment for this virus, there is an urgent need to learn from the experience and lessons in China. To reduce the case-fatality rate among COVID-19 patients, we should not ignore the complications, such as …
  • Coronavirus Disease 2019 (COVID-19) Pandemic and Pregnancy. [Journal Article]
    Am J Obstet Gynecol. 2020 Mar 23 [Online ahead of print]Dashraath P, Jing Lin Jeslyn W, … Lin SL
  • The current coronavirus disease 2019 (COVID-19) pneumonia pandemic, caused by the severe acute respiratory syndrome 2 (SARS-CoV-2) virus, is spreading globally at an accelerated rate, with a basic reproduction number (R0) of 2 - 2.5, indicating that 2 - 3 persons will be infected from an index patient. A serious public health emergency, it is particularly deadly in vulnerable populations and comm…
  • Teicoplanin: an alternative drug for the treatment of COVID-19? [Editorial]
    Int J Antimicrob Agents. 2020 Mar 13 [Online ahead of print]Baron SA, Devaux C, … Rolain JM
  • In December 2019, a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged from China causing pneumonia outbreaks, first in the Wuhan region of China and then spread worldwide because of its probable high transmission efficiency. Owing to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the b…
New Search Next